BH4 domain of Bcl-2 as a novel target for cancer therapy

Zhiqing Liu, Christopher Wild, Ye Ding, Na Ye, Haiying Chen, Eric A. Wold, Jia Zhou

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Overexpression of B cell lymphoma 2 (Bcl-2) proteins is associated with therapy resistance in various human cancers. Traditional approaches target the Bcl-2 homology (BH)3 domain of Bcl-2; however, the BH4 domain represents a superior therapeutic target in light of its unique structure and crucial involvement in many cellular functions. In this critical review, we focus on the structural and functional basis of targeting the BH4 domain of Bcl-2, and highlight the recent advances in drug discovery efforts toward small-molecule BH4 domain inhibitors (e.g. BDA-366). The proof-of-concept studies support the hypothesis that targeting the BH4 domain of Bcl-2 holds promise to offer a novel anticancer therapy through the induction of apoptosis and an increased potential to overcome therapeutic resistance.

Original languageEnglish (US)
JournalDrug Discovery Today
DOIs
StateAccepted/In press - 2015

Fingerprint

B-Cell Lymphoma
Neoplasms
Therapeutics
Drug Discovery
Apoptosis
Proteins

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

BH4 domain of Bcl-2 as a novel target for cancer therapy. / Liu, Zhiqing; Wild, Christopher; Ding, Ye; Ye, Na; Chen, Haiying; Wold, Eric A.; Zhou, Jia.

In: Drug Discovery Today, 2015.

Research output: Contribution to journalArticle

Liu, Zhiqing ; Wild, Christopher ; Ding, Ye ; Ye, Na ; Chen, Haiying ; Wold, Eric A. ; Zhou, Jia. / BH4 domain of Bcl-2 as a novel target for cancer therapy. In: Drug Discovery Today. 2015.
@article{c68f44dfe1ec4522b0ddd9d0d09ff8a6,
title = "BH4 domain of Bcl-2 as a novel target for cancer therapy",
abstract = "Overexpression of B cell lymphoma 2 (Bcl-2) proteins is associated with therapy resistance in various human cancers. Traditional approaches target the Bcl-2 homology (BH)3 domain of Bcl-2; however, the BH4 domain represents a superior therapeutic target in light of its unique structure and crucial involvement in many cellular functions. In this critical review, we focus on the structural and functional basis of targeting the BH4 domain of Bcl-2, and highlight the recent advances in drug discovery efforts toward small-molecule BH4 domain inhibitors (e.g. BDA-366). The proof-of-concept studies support the hypothesis that targeting the BH4 domain of Bcl-2 holds promise to offer a novel anticancer therapy through the induction of apoptosis and an increased potential to overcome therapeutic resistance.",
author = "Zhiqing Liu and Christopher Wild and Ye Ding and Na Ye and Haiying Chen and Wold, {Eric A.} and Jia Zhou",
year = "2015",
doi = "10.1016/j.drudis.2015.11.008",
language = "English (US)",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - BH4 domain of Bcl-2 as a novel target for cancer therapy

AU - Liu, Zhiqing

AU - Wild, Christopher

AU - Ding, Ye

AU - Ye, Na

AU - Chen, Haiying

AU - Wold, Eric A.

AU - Zhou, Jia

PY - 2015

Y1 - 2015

N2 - Overexpression of B cell lymphoma 2 (Bcl-2) proteins is associated with therapy resistance in various human cancers. Traditional approaches target the Bcl-2 homology (BH)3 domain of Bcl-2; however, the BH4 domain represents a superior therapeutic target in light of its unique structure and crucial involvement in many cellular functions. In this critical review, we focus on the structural and functional basis of targeting the BH4 domain of Bcl-2, and highlight the recent advances in drug discovery efforts toward small-molecule BH4 domain inhibitors (e.g. BDA-366). The proof-of-concept studies support the hypothesis that targeting the BH4 domain of Bcl-2 holds promise to offer a novel anticancer therapy through the induction of apoptosis and an increased potential to overcome therapeutic resistance.

AB - Overexpression of B cell lymphoma 2 (Bcl-2) proteins is associated with therapy resistance in various human cancers. Traditional approaches target the Bcl-2 homology (BH)3 domain of Bcl-2; however, the BH4 domain represents a superior therapeutic target in light of its unique structure and crucial involvement in many cellular functions. In this critical review, we focus on the structural and functional basis of targeting the BH4 domain of Bcl-2, and highlight the recent advances in drug discovery efforts toward small-molecule BH4 domain inhibitors (e.g. BDA-366). The proof-of-concept studies support the hypothesis that targeting the BH4 domain of Bcl-2 holds promise to offer a novel anticancer therapy through the induction of apoptosis and an increased potential to overcome therapeutic resistance.

UR - http://www.scopus.com/inward/record.url?scp=84949669843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949669843&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2015.11.008

DO - 10.1016/j.drudis.2015.11.008

M3 - Article

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -